glp-1 news 2025 october 21 RA Weight Loss Drugs May Carry Untold Ocular Burden GLP-1 Pipeline Update: November 2025

Incorporate balance exercises like single-leg stands or stability ball workouts

This aggressive marketing campaign contributed to the surge in off-label prescribing and the resulting wave of Ozempic injuries

It remains unclear if the benefits are from the drug itself or weight loss

Semaglutide dry mouth profile Semaglutide, marketed as Ozempic and Wegovy, carries a reporting-odds ratio of 1.34 for dry mouth in adverse event databases

Generic India strengths: 0.25 / 0.5 / 1 mg Both weekly subcutaneous, manufactured by Novo Nordisk

Approval timelines range from 1-10 business days depending on insurer complexity and documentation completeness